Craif Appoints Takeo Mukai as CFO, Hired Locally in the US
Bio-AI startup Craif Inc. has appointed Takeo Mukai, who has extensive experience in the US healthcare sector, as CFO. This local US hire aims to accelerate the company's global growth and business expansion in the US market for early cancer detection.
📋 Article Processing Timeline
- 📰 Published: April 24, 2026 at 17:00
- 🔍 Collected: April 24, 2026 at 08:31
- 🤖 AI Analyzed: April 24, 2026 at 08:51 (19 min after Collected)
Craif Inc. (Headquarters: Shinjuku-ku, Tokyo, Representative Director and CEO: Ryuichi Onose, hereinafter "Craif"), a bio-AI startup, announces the appointment of Takeo Mukai as Chief Financial Officer (CFO). Born in New York, Takeo Mukai is a Japanese-American executive with an extensive track record spanning finance, management, and the medical device industry. He has held CEO, COO, and CFO positions in the US healthcare sector and led successful exits for multiple companies. With the participation of a locally hired executive in the US—an uncommon move for a Japanese startup—Craif will further accelerate its non-linear global growth.
■ Background of the CFO Appointment
Craif aims to globally solve the challenge of "realizing a society where everyone can detect cancer early." The company has been building its business foundation in the US, the world's largest market and the leader in global life science standards. In Japan, the business is growing steadily, with preparations for regulatory submissions underway, implementations in over 2,400 medical institutions, adoptions by more than 5,000 drugstores, and public funding introductions by local governments. Backed by these achievements, Takeo Mukai was hired to accelerate business expansion in the US market as the next growth stage.
In the US, Craif is collaborating with 30 medical institutions across 15 states, looking ahead to insurance reimbursement in the field of early detection screening for pancreatic cancer. Moving forward, in addition to conducting large-scale clinical trials, it is essential to secure major funding, advance financial strategies, and build a robust corporate governance structure. To drive these initiatives, talent with extensive management experience in the US was required.
Takeo Mukai served as Finance Director across multiple strategic business units for approximately 14 years at Medtronic, the world's largest medical device manufacturer. He has since been involved in the management of multiple companies in the US healthcare sector, holding CxO roles and successfully leading corporate growth and exits. His domain knowledge and execution capabilities across the entire medical device industry, from product development to fundraising and M&A, will further strengthen the capabilities of Craif's management team. As Craif enters its next growth phase, he was recruited as CFO not only for his expertise and execution skills but also for his ability to drive management coordination across both the Japanese and US teams. Going forward, he will lead financial strategies, fundraising, corporate structuring, and the advancement of the US business.
■ About Takeo Mukai, CFO of Craif Inc.
After graduating from Carnegie Mellon University, he earned his MBA from the University of Southern California (USC). He started his career as a financial analyst at Ford Motor Company, then spent about 14 years at Medtronic, the world's largest medical device manufacturer. He served as Finance Director in several strategic business units, overseeing business finance totaling $1.2 billion annually and handling M&A due diligence. Following that, he led organizational transformation as CFO/CEO at Acutus Medical, and as CFO/COO at IRRAS, he guided the company to a strategic sale to ClearPoint Neuro. With extensive financial and management experience in the global medical device industry, he assumed the role of CFO at Craif Inc. in 2026.
■ Comment from Takeo Mukai, CFO of Craif
Craif is a company that combines a clear mission, outstanding science, and a team with execution capabilities. I was particularly drawn to the business foundation already established and the high quality of the team. I find it personally very meaningful to challenge the US market with technology originating from Japan. As CFO, I will contribute to building the financial foundation that supports growth and driving the US business.
■ Comment from Ryuichi Onose, CEO of Craif
There has not yet been an example of a Japanese startup achieving massive success in the US. I believe the key to succeeding in the US—the world's largest and most fiercely competitive market—lies in the founders committing locally and building a strong local team. Craif was founded by Dr. Yasui and myself, but we have formed a robust team including CTO Ichikawa and COO Mizunuma. I believe we are where we are today precisely because of this strong team. The quality of a team is often judged by glamorous resumes, but I believe a truly strong and successful team is one where people with high capabilities and strong will, regardless of their background, come together and work with their backs entrusted to each other under deep mutual trust.
Takeo has an impressive background, but that is secondary. The reason I wanted him to join the team is Craif's potential.
■ Background of the CFO Appointment
Craif aims to globally solve the challenge of "realizing a society where everyone can detect cancer early." The company has been building its business foundation in the US, the world's largest market and the leader in global life science standards. In Japan, the business is growing steadily, with preparations for regulatory submissions underway, implementations in over 2,400 medical institutions, adoptions by more than 5,000 drugstores, and public funding introductions by local governments. Backed by these achievements, Takeo Mukai was hired to accelerate business expansion in the US market as the next growth stage.
In the US, Craif is collaborating with 30 medical institutions across 15 states, looking ahead to insurance reimbursement in the field of early detection screening for pancreatic cancer. Moving forward, in addition to conducting large-scale clinical trials, it is essential to secure major funding, advance financial strategies, and build a robust corporate governance structure. To drive these initiatives, talent with extensive management experience in the US was required.
Takeo Mukai served as Finance Director across multiple strategic business units for approximately 14 years at Medtronic, the world's largest medical device manufacturer. He has since been involved in the management of multiple companies in the US healthcare sector, holding CxO roles and successfully leading corporate growth and exits. His domain knowledge and execution capabilities across the entire medical device industry, from product development to fundraising and M&A, will further strengthen the capabilities of Craif's management team. As Craif enters its next growth phase, he was recruited as CFO not only for his expertise and execution skills but also for his ability to drive management coordination across both the Japanese and US teams. Going forward, he will lead financial strategies, fundraising, corporate structuring, and the advancement of the US business.
■ About Takeo Mukai, CFO of Craif Inc.
After graduating from Carnegie Mellon University, he earned his MBA from the University of Southern California (USC). He started his career as a financial analyst at Ford Motor Company, then spent about 14 years at Medtronic, the world's largest medical device manufacturer. He served as Finance Director in several strategic business units, overseeing business finance totaling $1.2 billion annually and handling M&A due diligence. Following that, he led organizational transformation as CFO/CEO at Acutus Medical, and as CFO/COO at IRRAS, he guided the company to a strategic sale to ClearPoint Neuro. With extensive financial and management experience in the global medical device industry, he assumed the role of CFO at Craif Inc. in 2026.
■ Comment from Takeo Mukai, CFO of Craif
Craif is a company that combines a clear mission, outstanding science, and a team with execution capabilities. I was particularly drawn to the business foundation already established and the high quality of the team. I find it personally very meaningful to challenge the US market with technology originating from Japan. As CFO, I will contribute to building the financial foundation that supports growth and driving the US business.
■ Comment from Ryuichi Onose, CEO of Craif
There has not yet been an example of a Japanese startup achieving massive success in the US. I believe the key to succeeding in the US—the world's largest and most fiercely competitive market—lies in the founders committing locally and building a strong local team. Craif was founded by Dr. Yasui and myself, but we have formed a robust team including CTO Ichikawa and COO Mizunuma. I believe we are where we are today precisely because of this strong team. The quality of a team is often judged by glamorous resumes, but I believe a truly strong and successful team is one where people with high capabilities and strong will, regardless of their background, come together and work with their backs entrusted to each other under deep mutual trust.
Takeo has an impressive background, but that is secondary. The reason I wanted him to join the team is Craif's potential.